NCT00087672View on ClinicalTrials.gov

A Phase II Study of CC-5013 in Myelofibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Myelofibrosis

Interventions

DRUG

CC-5013

10 mg orally (2 capsules) daily

Trial Locations (1)

77030

M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00087672 - A Phase II Study of CC-5013 in Myelofibrosis | Biotech Hunter | Biotech Hunter